Ticker Symbol: EDIT
Editas Medicine Inc
$37.18 - 02-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001650664
Company Profile
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 11 Hurley St
Website: www.editasmedicine.com
CEO: Cynthia Collins
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $7.33
Change:
$0.19
(
2.66%)
Days Range: $7.06 - $7.46
Beta: 1.70
52wk. High: $14.23
52wk. Low: $6.33
Ytd. Change -16.84%
50 Day Moving Average: $7.72
200 Day Moving Average: $8.49
Shares Outstanding: 81632619
Valuation
Market Cap: 59.8B
PE Ratio: -2.48
EPS (TTM): -2.96
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A